Home Authors Posts by Hans-Georg Lerchen

Hans-Georg Lerchen

Hans-Georg Lerchen is Chief Scientist in the Medical Chemistry department in the R&D organization of Bayer AG, Pharmaceuticals Division. With a 31 years background in MedChem he is author or co-author of 80 patents or patent applications and 21 publications. His current research focus is drug delivery modalities, prodrugs and in particular antibody drug conjugates.
1 POSTS 0 COMMENTS
Hans-Georg Lerchen is Chief Scientist in the Medical Chemistry department in the R&D organization of Bayer AG, Pharmaceuticals Division. With a 31 years background in MedChem he is author or co-author of 80 patents or patent applications and 21 publications. His current research focus is drug delivery modalities, prodrugs and in particular antibody drug conjugates.
Bayer researchers in one of Bayer’s cell culture laboratories in Berlin, Germany. Courtesy: Bayer

Antibody-drug Conjugates with Novel Kinesin Spindle Protein Inhibitor Payloads and a...

Hans-Georg Lerchen
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X